US Patent

US9526726 — Aripiprazole formulations having increased injection speeds

Formulation · Assigned to Alkermes Pharma Ireland Ltd · Expires 2035-03-19 · 9y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions for the intramuscular delivery of antipsychotic drugs, such as aripiprazole, using rapid injection rates.

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.

Drugs covered by this patent

Patent Metadata

Patent number
US9526726
Jurisdiction
US
Classification
Formulation
Expires
2035-03-19
Drug substance claim
No
Drug product claim
Yes
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.